You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

 

Online download statistics by month:

Online download statistics by month: August 2021 to July 2025

AbstractFullPdf
Aug 202111021113307
Sep 2021354355153
Oct 202131231265
Nov 202133933862
Dec 202132432443
Jan 202226426870
Feb 202225125660
Mar 202214414947
Apr 202214314562
May 202212113351
Jun 202215916039
Jul 202224324453
Aug 202234334784
Sep 202226826755
Oct 202220220247
Nov 202219419762
Dec 202218919038
Jan 202316316532
Feb 202313713738
Mar 202313013141
Apr 202311711740
May 202310110138
Jun 202313713940
Jul 202314914949
Aug 202312412326
Sep 2023909038
Oct 2023989838
Nov 202310110135
Dec 202310410637
Jan 2024838437
Feb 2024929243
Mar 2024909066
Apr 2024888851
May 2024989846
Jun 2024949746
Jul 202413513649
Aug 2024565234
Sep 2024363625
Oct 2024586448
Nov 2024727343
Dec 2024909446
Jan 2025868638
Feb 2025646443
Mar 2025797937
Apr 202510910953
May 2025717257
Jun 2025505023
Jul 2025110
Total785579222535